The Relentless Progression of Metabolic Dysfunction–associated Steatotic Liver Disease in Liver Transplantation in Spain
Laura Martínez‐Arenas(Instituto de Salud Carlos III), Marina Berenguer(Hospital Universitari i Politècnic La Fe), Ângela Carvalho‐Gomes(Instituto de Salud Carlos III), Sara Lorente(Hospital Clínico Universitario Lozano Blesa), Fernando Díaz‐Fontenla(Hospital General Universitario Gregorio Marañón), Nazia Selzner(University Health Network), Danielle Brandman(University of California, San Francisco), Sanjaya K. Satapathy(Northwell Health), Kymberly D. Watt(Mayo Clinic), Marta Guerrero-Misas(Instituto Maimónides de Investigación Biomédica de Córdoba), Saleh Elwir(Baylor University Medical Center), Enrique Vidal(Leitat Technological Center), Coleman I. Smith(Georgetown University), J.I. Herrero(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Mary E. Rinella(Northwestern University), Mohammad Shadab Siddiqui(Virginia Commonwealth University)
Cited by 0
Related Papers
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
The global burden of metabolic disease: Data from 2000 to 2019
|Cell Metabolism|2023|777
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
|Clinical Gastroenterology and Hepatology|2018|593
Protective strategies against ischemic injury of the liver
|Gastroenterology|2003|544